01—Abstract
Summary
Summary of the 8-K filed November 12, 2024. Cited figures are marked; the original filing is the authoritative source.
On November 11, 2024, Cardinal Health (CAH) agreed to acquire approximately 71% of GI Alliance (GIA), the largest gastroenterology management services organization in the U.S., for about $2.8 billiona in cash, subject to adjustment.
The deal is subject to HSR antitrust clearance and other customary closing conditions, and the company expects it to close in early calendar 2025. Cardinal also agreed to acquire the Advanced Diabetes Supply Group (ADSG) for roughly $1.1 billionb in cash, which will merge into its at-Home Solutions business. Management says both deals should be accretive to revenue, segment profit growth and non-GAAP EPS within 12 months of closing, and expects to reflect them in fiscal 2025 guidance upon close.
The transactions are financed through a $2.9 billionc 364-day senior unsecured bridge facility from Bank of America, plus cash on hand and new debt. Closing is not conditioned on financing. Cardinal plans to pay down debt over the next 18 to 24 months while preserving its investment-grade ratings and said the deleveraging will not change previously outlined fiscal 2025 share repurchases.
The 8-K also discloses a $20 milliond termination fee in certain circumstances and a call right, beginning on the third anniversary of the GIA closing, to buy the remaining GIA equity at fair market value. The filing signals a strategic push into specialty and home-based care, building on recent acquisitions of Specialty Networks and Integrated Oncology Network.
Investors should weigh the meaningful leverage increase against the expected earnings contribution, and note that the Merger Agreement's representations are contract terms rather than verified facts about the companies. A June 12, 2025 Investor Day has been scheduled to provide more detail.
02—Key points
Key Highlights
- Acquisition of ~71% of GI Alliance for ~$2.8 billion in cash, subject to adjustment; GIA becomes a platform within the Pharmaceutical and Specialty Solutions segment
- Acquisition of Advanced Diabetes Supply Group for ~$1.1 billion in cash, to be merged into the at-Home Solutions business
- Financing via a $2.9 billion 364-day senior unsecured bridge facility from Bank of America; closing is not conditioned on financing
- Both deals expected to close in early calendar 2025, subject to HSR clearance and customary conditions, and to be accretive to revenue, segment profit growth and non-GAAP EPS within 12 months of close
- Management plans to pay down debt over 18 to 24 months, maintain investment-grade ratings, and keep previously outlined fiscal 2025 share repurchases
- Merger Agreement includes a $20 million termination fee in certain circumstances and a fair-market-value call right on the remaining GIA equity beginning on the third anniversary of closing
- Investor Day scheduled for June 12, 2025 in New York City
03—Questions
Frequently Asked Questions
How much is Cardinal Health paying for GI Alliance and what stake does it get?
Cardinal agreed to acquire about 71% of GI Alliance for approximately $2.8 billion in cash, subject to adjustment. The remaining equity is held by GIA physician owners and funds affiliated with Apollo.
How will Cardinal Health finance these acquisitions?
Bank of America has committed a $2.9 billion 364-day senior unsecured bridge term loan. Management intends to fund the deals with a combination of cash on hand and new debt, and plans to pay down debt over the next 18 to 24 months.
What could prevent the deals from closing?
Closing depends on expiration of the HSR Act waiting period and other customary conditions, including required regulatory approvals. Financing is not a closing condition, and a $20 million termination fee may apply in certain circumstances.
Will these acquisitions affect share buybacks?
Management said the deleveraging plan is not expected to change the share repurchases it previously outlined for fiscal year 2025.
When will the deals affect Cardinal Health's financial results?
The company expects the transactions to close in early calendar 2025 and to reflect them in fiscal 2025 guidance upon closing. It expects them to be accretive to non-GAAP EPS within the first 12 months after close, but does not provide GAAP guidance for them.
04—Continue